The Danish drugmaker keeps particular numbers on market capacity, however the business is the very first to provide GLP-1 to deal with fatty liver that affects 5% of the United States populace.
发布者:BY Jens Valbjorn Stavnsbjerg,转转请注明出处:https://robotalks.cn/novo-nordisk-notes-great-potential-for-wegovy-in-new-us-mash-market/